Jasper Therapeutics, Inc. (JSPR) Dividend History

Jasper Therapeutics, Inc. (JSPR) is a biotechnology company focused on developing therapies for hematopoietic stem cell transplantation. The company's primary goal is to improve conditioning regimens and expand treatment options for patients with blood disorders, including sickle cell disease, thalassemia, and certain malignancies. Jasper applies its proprietary technologies to create targeted conditioning agents and stem cell therapies to enhance transplant safety and efficacy.

2200 Bridge Pkwy Suite #102, Redwood City, CA, 94065
Phone: (650) 549-1400
Website: https://www.jaspertherapeutics.com

Dividend History

Jasper Therapeutics, Inc. currently does not pay dividends

Company News

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

    Pomerantz LLP is investigating potential securities fraud at Jasper Therapeutics after the company reported data confoundment issues in a drug study, causing a 55.1% stock price drop.

    GlobeNewswire Inc.
  • Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know

    Jasper Therapeutics (JSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Zacks Investment Research
  • Over $15M Bet On Aon? Check Out These 3 Stocks Insiders Are Buying

    Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Jasper Therapeutics The Trade: Jasper Therapeutics, Inc. (NASDAQ: JSPR) 10% owner Adam Morgan acquired a total of 350,000 shares an average price ...

    Benzinga
    Featured Companies: AON
  • 5 Penny Stocks To Buy According To Analysts, Targets Up To 952%

    Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: PGEN TDUP
Page data last updated 07/23/2025 16:08:30 UTC